GADL1 has 61% homology with another PLP-dependent enzyme cysteine sulfinic acid decarboxylase (CSAD).[8] CSAD plays a role in taurine production by decarboxylating CSA to hypotaurine. Taurine is the most abundant amino acid in mammals and plays roles as an antioxidant, membrane stabilizer and neurotransmitter or neuromodulator in the CNS[9] and recently has received growing attention as a biomarker for different diseases.[10]
In humans, both GADL1 and CSAD are expressed in the brain and neurons whereas only CSAD was found in the liver. In mice, both enzymes are expressed in the brain, olfactory bulbs, and skeletal muscle but only CSAD was found in the kidney and liver.
GADL1 is named ADC, CSADC, HuADC, HuCSADC in some papers.
Both CSAD and GADL1 are homodimers. The structure of mouse GADL1 was published in 2018 with the PDB number 6ENZ [11] and the structure of mouse CSAD was published in 2021 with the PDB number 6ZEK.[12]
In 2014 a paper showed an association between GADL1 variants and bipolar patients' responses to lithium therapy.[13] Although these findings were not replicable, this article triggers more studies on GADL1. So far there has not been any paper published reporting reproducible data on the therapeutic role of GADL1. However, this novel PLP-dependent enzyme has a high potential for further investigation.
